Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study

Conclusion.Our findings confirm that in AA, surgical local control may be challenging, with a significant rate of local relapse despite complete surgery. Hormone therapy is an active treatment option, with a potential of disease control and of being combined with surgery. The addition of an AI to first‐line GnRHa could be an effective second‐line systemic therapy in premenopausal female patients with AA.Implications for Practice.In this retrospective effort including 36 patients with aggressive angiomyxoma, local relapse rate after complete surgery was 50%, with a median relapse‐free survival of 39 months, confirming that local control is challenging. Overall response rate to first‐line hormone therapy was 62%, with a median progression‐free survival of 24.6 months. Thus, hormone therapy has a potential of disease control and of being combined with surgery.

Source: The Oncologist - July 16, 2019 Category: Cancer & Oncology Authors: Giovanni Fuca, Nadia Hindi, Isabelle Ray-Coquard, Vittoria Colia, Angelo Paolo Dei Tos, Javier Martin-Broto, Mehdi Brahmi, Paola Collini, Domenica Lorusso, Francesco Raspagliesi, Maria Abbondanza Pantaleo, Bruno Vincenzi, Elena Fumagalli, Alessandro Gronc Tags: Sarcomas Source Type: research